edotreotide: clinical use

Prescribing considerations

• Diagnostic use only; authorised personnel must handle and administer it in a designated nuclear medicine facility.
• Justify radiation exposure for each patient.
• Ensure good hydration and frequent bladder emptying.
• Confirm pregnancy status where relevant and coordinate imaging with somatostatin analogue treatment.
• Interpret uptake cautiously because normal organs, inflammation, other tumours, splenic tissue and some recent vaccination-related lymph nodes may show uptake.

Contraindications and cautions

• Hypersensitivity to edotreotide, an excipient or any component of the labelled radiopharmaceutical.

Monitoring

• Check for prior hypersensitivity and ensure immediate access to resuscitation equipment.
• Assess renal or hepatic impairment because pharmacokinetics are uncharacterised and radiation exposure may be increased.
• Monitor the injection site for extravasation and local irritation.
• Correlate positive uptake with clinical findings and other relevant investigations when needed.

Clinical pharmacology

Gallium-68 edotreotide binds with high affinity mainly to SSTR2 and, to a lesser extent, SSTR5. It is rapidly cleared from blood and excreted through the kidneys as intact compound. No clinically relevant pharmacodynamic action is expected at diagnostic concentrations.

Formulation and product differences

• Supplied as a radiopharmaceutical preparation kit containing edotreotide powder and a separate reaction buffer.
• The radionuclide is not included; the kit must be radiolabelled with compatible gallium-68 chloride before intravenous administration.
• The vial contents must never be administered without preparation and radiolabelling.
• The prepared product is for single-patient use under aseptic and radiation-protection controls.